Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac resynchronization therapy: caveat medicus!

Mandeep R Mehra1, Barry H Greenberg

  • 1Department of Cardiovascular Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA. mmehra@ochsner.org

Journal of the American College of Cardiology
|April 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory.

JACC. Heart failure·2025
Same author

Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights From RELAX-AHF-2.

Journal of cardiac failure·2025
Same author

Clinical Presentation, Biomarker Trajectories, and Outcomes in Women and Men Hospitalized for Acute Heart Failure.

JACC. Heart failure·2025
Same author

End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2).

European journal of heart failure·2024
Same author

Decongestion and Outcomes in Patients Hospitalized for Acute Heart Failure: Insights From the RELAX-AHF-2 Trial.

JACC. Heart failure·2024
Same author

Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design.

JACC. Heart failure·2024
Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026
Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026
Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026
Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026
Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026
Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026
See all related articles

Cardiac resynchronization therapy improves heart failure outcomes but has a significant placebo effect and variable patient response. Optimal patient selection and lead placement are crucial for effective treatment.

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Management

Background:

  • The device era in heart failure is advancing with pacemakers, defibrillators, and ventricular assist devices.
  • Cardiac resynchronization therapy (CRT) aims to improve ventricular contractility by reducing dyssynchrony.
  • Recent trials indicate CRT benefits include improved function, reversed ventricular remodeling, and fewer hospitalizations.

Purpose of the Study:

  • To evaluate the effectiveness and identify limitations of current cardiac resynchronization therapy approaches.
  • To highlight the need for precise detection and targeting of mechanical dyssynchrony.
  • To emphasize the importance of optimizing CRT for patient benefit.

Main Methods:

  • Analysis of recent cardiac resynchronization therapy trials.

Related Experiment Videos

  • Assessment of functional capacity, ventricular remodeling, and hospitalization rates.
  • Evaluation of placebo effects and response heterogeneity in CRT.

    • Main Results:

    • CRT shows benefits but also a substantial placebo effect, impacting nearly half of the control group.
    • Significant heterogeneity of response and a high non-responder rate were observed across trials.
    • Current CRT approaches are considered 'best guess' due to reliance on surrogate responses.

    Conclusions:

    • Effective CRT requires more than device implantation; precise identification and pacing of mechanical dyssynchrony are key.
    • Further research is essential to refine CRT strategies and identify patients most likely to benefit.
    • Optimizing CRT delivery is critical to ensure positive clinical outcomes in heart failure patients.